DelNova: Addressing complications from Botox (217)

DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.

– Apple
– Spotify


Recent Posts

Angels Don’t Invest Late Stage

We occasionally hear individual investors suggest something like “I invest in later stage companies.” or…

Top Specialties in Private Practice Settings

Despite all of the momentum toward becoming employed physicians, the report noted below reminds us…

Google Health Ramps

Want to know how Google is thinking about their role in healthcare? The following statement…